Correlation analysis between clinical classification and TCM constitution in 69 cases of drug⁃induced liver injury

ZHANG Chun; LI Li; WANG Yitong

doi:10.16305/j.1007-1334.2023.2210021

您当前的位置：

首页 >

文章列表页 >

Correlation analysis between clinical classification and TCM constitution in 69 cases of drug⁃induced liver injury

更新时间：2023-05-16

- Correlation analysis between clinical classification and TCM constitution in 69 cases of drug⁃induced liver injury
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 5, Pages: 27-30(2023)
- 作者机构：
  
  1.首都医科大学附属北京佑安医院中西医结合中心（北京 100069）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2210021
  CLC：
扫描看全文
张纯,李丽,王一同.69例药物性肝损伤患者临床分型与中医体质的相关性分析[J].上海中医药杂志,2023,57(5):27-30.

ZHANG Chun,LI Li,WANG Yitong.Correlation analysis between clinical classification and TCM constitution in 69 cases of drug⁃induced liver injury[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):27-30.
张纯,李丽,王一同.69例药物性肝损伤患者临床分型与中医体质的相关性分析[J].上海中医药杂志,2023,57(5):27-30. DOI： 10.16305/j.1007-1334.2023.2210021.

ZHANG Chun,LI Li,WANG Yitong.Correlation analysis between clinical classification and TCM constitution in 69 cases of drug⁃induced liver injury[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(5):27-30. DOI： 10.16305/j.1007-1334.2023.2210021.

摘要

目的,2,分析药物性肝损伤患者临床分型与中医体质的相关性。,方法,2,借助医院住院病历系统收集药物性肝损伤患者的一般资料（年龄、性别、过敏史等）、实验室指标、导致肝损伤的药物信息及中医体质资料，根据R值进行临床分型（肝细胞损伤型、胆汁淤积型、混合型），结合调查问卷结果（电话随访）根据相关标准进行中医体质分类（平和质、气虚质、气郁质、阳虚质、阴虚质、湿热质、痰湿质、血瘀质、特禀质）。采用Logistic回归分析方法分析药物性肝损伤临床分型与中医体质的相关性。,结果,2,①本研究共纳入69例药物性肝损伤患者，女性为多（76.8%），女性平均年龄（51.06,±,12.19）岁、男性平均年龄（45.88,±,12.51）岁，有过敏史者11例。②临床分型肝细胞损伤型29例，胆汁淤积型23例，混合型17例。③中药及其制剂［多含何首乌（61.9%）、雷公藤（28.6%）］、解热镇痛类药物、保健品引起的药物性肝损伤居多（分别占30.4%、15.9%、13.0%）。④69例患者以平和质、气虚质、特禀质、气郁质居多，分别占39.1%、15.9%、14.5%、13.0%。⑤特禀质与肝细胞损伤型（,P,<,0.05）、胆汁淤积型（,P,<,0.05）临床分型有相关性，是影响药物性肝损伤胆汁淤积型临床分型的相关因素［,OR,=6.271，95%,CI,（1.443，27.253）］。,结论,2,特禀质药物性肝损伤患者易出现胆汁淤积，临床对于特禀质人群选方用药应更加谨慎，一旦发生药物性肝损伤，除及时停药外，还应积极给予祛除胆汁淤积、抑制免疫炎症风暴相关治疗，防止病情迅速进展。

Abstract

Objective,2,To analyze the clinical classification of patients with drug-induced liver injury （DILI） and its correlation with TCM constitution.,Methods,2,General data （age， gender， and history of allergy， etc.）， laboratory indicators， drug information causing liver injury and TCM constitutions of patients with DILI were collected through hospital inpatient medical record system. Clinical classification （hepatocellular injury type， cholestasis type， and mixed type） was conducted according to R value. TCM constitution （normal type， qi-deficiency type， qi-stagnation type， yang-deficiency type， yin-deficiency type， damp-heat type， phlegm-damp type， blood stasis type， and special endowment type） was classified according to relevant criteria and the results of the questionnaire （telephone follow-up）. Logistic regression analysis was used to analyze the correlation between clinical classification and TCM constitution in DILI cases.,Results,2,①A total of 69 DILI cases were included in this study， and 76.8% were female with an average age of （51.06±12.19） years， while the average age of men was （45.88±12.51） years. There were 11 cases with a history of allergy. ②There were 29 cases of hepatocellular injury type， 23 cases of cholestasis type， and 17 cases of mixed type. ③Most DILI was caused by traditional Chinese herbal medicines （TCHMs） and preparations ［mostly containing Polygoni Multiflori Radix （61.9%） and Tripterygium wilfordii （28.6%）］， antipyretic and analgesic drugs， and health care products （30.4%， 15.9%， and 13.0%， respectively）. ④The majority constitution types of 69 patients were normal type， qi-deficiency type， special endowment type and qi-stagnation type （39.1%， 15.9%、14.5% and 13.0%， respectively）. ⑤The special endowment type was correlated with the clinical classification of hepatocellular injury type （,P,<,0.05） and the cholestasis type （,P,<,0.05）， and was a relevant factor influencing the cholestasis type of DILI ［,OR,=6.271，95%,CI,（1.443，27.253）］.,Conclusions,2,DILI patients of the special endowment type are more likely to have cholestasis. Clinical treatment should be more cautious in selecting prescriptions and medications for patients of the special endowment type. Once DILI occurs， active treatment should be given to remove cholestasis and inhibit immunoinflammtory storm to prevent rapid progression of the disease in addition to timely withdrawal of drugs.

关键词

药物性肝损伤临床分型中药中医体质相关性分析

Keywords

drug-induced liver injury （DILI）clinical classificationtraditional Chinese herbal medicineTCM constitutioncorrelation analysis

references

BJORNSSON E S， BERGMANN O M， BJORNSSON H K， et al. Incidence， presentation， and outcomes in patients with drug-induced liver injury in the general population of Iceland［J］. Gastroenterology， 2013， 144（7）： 1419-1425.

HAQUE T， SASATOMI E， HAYASHI P H. Drug-induced liver injury： pattern recognition and future directions［J］. Gut Liver， 2016， 10（1）： 27-36.

STINE J G，LEWIS J H. Drug-induced liver injury： a summary of recent advances［J］. Expert Opin Drug Metab Toxicol， 2011， 7（7）： 875-890.

LUCENA M I， ANDRADE R J， KAPLOWITZ N， et al. Phenotypic characterization of idiosyncratic drug-induced liver injury： the influence of age and sex［J］. Hepatology， 2009， 49 （6）： 2001-2009.

AZIZI F， AMOUZEGAR A. Management of hyperthyroidism during pregnancy and lactation［J］. Eur J Endocrinol， 2011， 164 （6）： 871-876.

SINGLA R， SHARMA S K， MOHAN A， et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity［J］. Indian J Med Res， 2010， 132： 81-86.

FROMENTY B. Drug-induced liver injury in obesity［J］. J Hepatol， 2013， 58（4）： 824-826.

沈弢，段昭君，庄辉. 药物性肝损伤的流行病学［J］. 肝脏，2015， 20（10）： 819-823.

于乐成，茅益民，陈成伟. 药物性肝损伤诊治指南［J］. 实用肝脏病杂志，2017， 20（2）： 257-274.

DEVABHAVI H， AITHAL G， TREEPRASERTSUK S， et al. Drug-induced liver injury： Asia Pacific Association of Study of Liver consensus guidelines［J］. Hepatol Int， 2021， 15（2）： 258-282.

HOU F Q， ZENG Z， WANG G Q. Hospital admissions for drug-induced liver injury： clinical features， therapy， and outcomes［J］. Cell Biochem Biophys， 2012， 64（2）： 77-83.

王琦. 中医体质学［M］. 北京：人民卫生出版社，2009：2348.

中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南［J］. 中华肝脏病杂志，2015， 23（11）： 810-820.

中华中医药学会. 中医体质分类与判定：ZYYXH/T 157—2009［S］. 北京：中华中医药学会，2009.

王海珍，李秀惠. 药物性肝损伤发病机制研究进展［J］. 临床肝胆病杂志，2018， 34（4）： 883-887.

NAGA C， EINAR B. Risk ractors for idiosyncratic drug-induced liver injury［J］. Gastroenterology， 2010， 138（7）： 2246-2259.

羊菲，金若敏. 基于中药特点的肝毒性研究与思考［J］. 上海中医药大学学报，2020， 34（1）： 1-10.

苏俊. 特禀体质流行病学初步研究［D］. 北京：北京中医药大学，2007.

潘雨，尚晓玲. 特禀质与肺系及过敏性疾病的相关性研究［J］. 吉林中医药，2020， 40（10）： 1289-1291.

陈静，李亚利，梁欣，等. 96例药物性肝损伤临床特点分析及危险因素探讨［J］. 临床药物治疗杂志，2017， 15（2）： 19-23.

DEVABHAVI H. An update on drug-induced liver injury［J］. J Clin Exp Hepatol， 2012， 2（3）： 247-259.

傅青春. 药物性胆汁淤积［J］. 肝脏，2000， 5（1）： 29-30.

中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识（2015）［J］. 临床肝胆病杂志，2015， 31（12）： 1989-1999.

孔艳，孔祥. 妊娠期肝内胆汁淤积症免疫因素的研究进展［J］. 中华妇幼临床医学杂志（电子版），2015， 11（6）： 798-800.

吴文晓，王婷，耿兴超，等. 药物性胆汁淤积型肝损伤的研究进展［J］. 中国新药杂志，2020， 29（2）： 143-151.

茅益民. 解读ACG临床指南：“特异质型药物性肝损伤的诊断和管理”［J］. 胃肠病学，2015， 20（4）： 193-198.

王济，李玲孺，李英帅，等. 树突状细胞成熟及其表观遗传调节理论在中医特禀体质（过敏体质）研究中的应用［J］. 中华中医药杂志，2014， 29（3）： 683-685.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress in anti⁃tumor clinical efficacy and mechanism of action of Sarcandrae Herba

Mechanism of Astragaloside Ⅳ regulates extracellular vesicles⁃mediated JMJD3/H3K27me3/OPN pathway against colorectal cancer liver metastasis

Research progress in anti⁃tumor regulation of metabolic reprogramming by active components of traditional Chinese herbal medicines

Research progress in monomers of traditional Chinese herbal medicine targeting PI3K/Akt/mTOR signaling pathway to prevent and treat diabetic nephropathy

Research progress on alkaloid active ingredients in Nelumbinis Folium against non‑alcoholic fatty liver disease

Related Author

No data

Related Institution

Sichuan Institute for Translational Chinese Medicine

Shanghai University of Traditional Chinese Medicine

Department of Medical Oncology & Cancer Institute of Integrative Medicine， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology I， Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Key Laboratory of Liver and Kidney Diseases， Ministry of Education

⁰